The Oligonucleotide Solid Phase Synthesizer Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 3.5 billion by 2034, registering a CAGR of 11.5%. This growth trajectory is underpinned by several factors, including advancements in biotechnology, increasing demand for personalized medicine, and the rising prevalence of genetic disorders. The market is witnessing a surge in...